Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.4123
-0.0144 (-3.37%)
At close: Aug 6, 2025, 4:00 PM
0.4078
-0.0045 (-1.09%)
After-hours: Aug 6, 2025, 7:54 PM EDT
Chimerix Stock Forecast
CLSD's stock price has decreased by -62.17% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Chimerix stock have a consensus rating of "Hold" and an average price target of $4.33, which forecasts a 950.21% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $5.00.
Price Target: $4.33 (+950.21%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Chimerix stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $5 | Strong Buy → Hold | Downgrades | $5 | +1,112.71% | Jul 18, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $3 | Strong Buy → Hold | Downgrades | $3 | +627.63% | Jul 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,112.71% | May 23, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +1,112.71% | May 16, 2025 |
Financial Forecast
Revenue This Year
2.97M
from 1.66M
Increased by 78.37%
Revenue Next Year
3.50M
from 2.97M
Increased by 17.79%
EPS This Year
-0.42
from -0.47
EPS Next Year
-0.62
from -0.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.7M | 21.3M | 34.9M | ||
| Avg | 3.0M | 3.5M | 14.8M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 120.9% | 617.8% | 899.5% | ||
| Avg | 78.4% | 17.8% | 323.9% | ||
| Low | 35.5% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.19 | -0.21 | -0.24 | ||
| Avg | -0.42 | -0.62 | -0.51 | ||
| Low | -0.62 | -1.27 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.